Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T22350
|
||||
| Former ID |
TTDR00642
|
||||
| Target Name |
Endoglin
|
||||
| Gene Name |
ENG
|
||||
| Synonyms |
CD105; CD105 antigen; ENG
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Fallopian tube cancer; Peritoneal cancer; Macular degeneration; Ovarian cancer [ICD9:140-229, 183.2, 221.0, 362.5, 183; ICD10: C57, D28, H35.3, C56] | ||||
| Function |
Major glycoprotein of vascular endothelium. Involved in the regulation of angiogenesis. May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Acts as TGF-beta coreceptor and is involved in the TGF- beta/BMP signaling cascade. Required for GDF2/BMP9 signaling through SMAD1 in endothelial cells and modulates TGF-beta1 signaling through SMAD3.
|
||||
| BioChemical Class |
Zona pellucida-like
|
||||
| UniProt ID | |||||
| Sequence |
MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNA
ILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAY NSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLS FCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVEL SCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLL GEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQ TKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASM ISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVS PSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVP IPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAF LIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | TRC 105 | Drug Info | Phase 2 | Fallopian tube cancer; Peritoneal cancer; Macular degeneration; Ovarian cancer | [1] |
| Modulator | TRC 105 | Drug Info | [2] | ||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.